Skip to main content
Top

2006 | OriginalPaper | Hoofdstuk

Welk risico bestaat er op ontwikkeling van diabetes mellitus bij toepassing van atypische antipsychotica?

Auteur : drs. G. van den Brink

Gepubliceerd in: Vademecum permanente nascholing huisartsen

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

De afgelopen jaren is er veel gepubliceerd over de verstoringen van de glucose- en vethuishouding en het ontstaan van diabetes mellitus als complicatie van de toepassing van de atypische antipsychotica. Op deze relatie zal worden ingegaan.
Literatuur
go back to reference Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatrica Sandinavica 2009; 119: 4–14. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatrica Sandinavica 2009; 119: 4–14.
go back to reference American Diabetes Association et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psych 2004; 65: 267–72. American Diabetes Association et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psych 2004; 65: 267–72.
go back to reference Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
go back to reference Yood MU, DeLorenze G, Quesenberry CP, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent – results from a multisite epidemiologic study. Pharmacoepidemiol Drug Safety 2009 (ahead of print). Yood MU, DeLorenze G, Quesenberry CP, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent – results from a multisite epidemiologic study. Pharmacoepidemiol Drug Safety 2009 (ahead of print).
go back to reference Guo JJ, Keck PE, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy 2007; 27: 27–35. Guo JJ, Keck PE, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy 2007; 27: 27–35.
go back to reference Smith M, Hopkins D, Peveler RC, et al. First- vs. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psych 2008; 192: 406–11. Smith M, Hopkins D, Peveler RC, et al. First- vs. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psych 2008; 192: 406–11.
go back to reference Buchholz S, Morrow AF, Coleman PL. Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Int Med J 2008; 38: 602–06. Buchholz S, Morrow AF, Coleman PL. Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Int Med J 2008; 38: 602–06.
Metagegevens
Titel
Welk risico bestaat er op ontwikkeling van diabetes mellitus bij toepassing van atypische antipsychotica?
Auteur
drs. G. van den Brink
Copyright
2006
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8808-0_1023